Subcribe Here!

Enter your email address. It;s free!

Delivered by FeedBurner

Netizen 24 AUS: What is "right to try" and will it help terminally ill patients?

Posted by On 10:41 AM

What is "right to try" and will it help terminally ill patients?


In this March 18, 2011 photo, Cassidy Hempel waved at hospital staff as she was being treated for a rare disorder, Niemann Pick Type C disease. Her mother Chris, left, fought to gain permission for an experimental drug.

Last Updated May 30, 2018 1:01 PM EDT

Morten Wendelbo is a lecturer at the Bush School of Government and Public Service and a research fellow at the Scowcroft Institute of International Affairs at Texas A&M University; Timothy Callaghan is an assistant professor at Texas A&M University Health Science Center.

After a year in which President Donald Trump devoted much of his health policy attention to efforts to repeal and replace the Affo rdable Care Act, Mr. Trump used part of his State of the Union address in January to press Congress to focus attention in 2018 on a new health priority â€" the passage of "right to try" legislation. It passed, and the president signed it today.

Right to try legislation gives terminally ill patients the right to use experimental medications that have not yet been approved by the Food and Drug Administration.

President Trump's push for the passage of right to try nationally builds on the efforts of the libertarian-leaning Goldwater Institute, which has used the broad popularity of the policy to help achieve passage of similar legislation in 38 states, although the state legislation differs substantially from the version now on the president's table.

  • Twins with rare genetic disorder could hold clue to cure for Ebola

Despite these state gains and the policy's growing popularity among states, ethical questions remain about the tangible impact of a federal right to try law on Americans with terminal illnesses. Most notably, a growing body of evidence from policy analysts argues that the legislation would unfortunately accomplish very little change for most patients, and it could actually make it harder to get new drugs approved in the future.

How the drug approval process works

Pharmaceuticals in the United States are regulated by the FDA. When a drug company develops a new compound intended for patient use, the medication goes through three phases of clinical trials that often take years to complete.

The first phase of trials requires a company to prove the drug is relatively safe for humans â€" that the drug itself will not poison the patient. These phase 1 trials are often conducted on as few as 30 patients.

In later phases, the clinical trials test whether the drug is effective at treating the condition for which it is intended without problematic side effects. It is at t his stage that the vast majority of drugs fail to pass approval, because many drugs turn out to be ineffective or to cause severe side effects.

The right to try legislation the Trump administration pushed for would authorize doctors to administer drugs that have cleared the first phase, but which have not yet completed these later human clinical trials. By doing so, the legislation gives terminally ill patients the right to use potentially lifesaving medications without rigorous testing from the FDA and without years of waiting for the drugs to become commercially available.

For people suffering from terminal conditions such as amyotrophic lateral sclerosis, or ALS, for which there are promising treatments in the midst of the approval process, the legislation brings hope.

That said, we believe the promises made by right to try advocates are far greater than the actual impact it will have on patients.

"Right to try" grants no real rights

Despite good intentions â€" and the legislation's name â€" right to try legislation grants no rights. It would merely grant permission for a patient to try to get experimental medication from a pharmaceutical company.

Patients would be allowed to try experimental drugs, but nothing in the legislation would make it mandatory for pharmaceutical companies to provide these medications.

The reasons for a company to withhold a drug are many. Giving access to preapproval drugs can be costly, particularly given the limited supply, and almost no medical insurance will cover experimental treatments. Access to the drugs will likely only be feasible for wealthy Americans who can afford to pay for the treatment, as well as the consequences of any negative side effects out of pocket.

Many drug companies also worry that making the drug available without approval opens them up to lawsuits if the drugs prove ineffective or have unforeseen side effects. The current federal rig ht to try proposal does provide some protections for companies in this regard, but until those protections have been tested in court, it is likely companies will remain cautious.

Providing the drug to patients outside of clinical trials can also be disruptive to the approval process because it can lead to data on negative clinical outcomes outside the highly controlled trial setting. While new legislation prevents this data from being used unless it is deemed "critical to determining safety," bad outcomes might give the FDA pause and delay the approval of drugs that might otherwise be available sooner.

The "right to try" legislation changes very little

Beyond these issues, federal right to try legislation will have minimal impact on the availability of experimental drugs for patients. Not only have 38 states already passed similar legislation, but the FDA already has a program in place designed to provide patients with experimental medicatio ns.

This program, known as the "compassionate use" program, performs essentially the same function as the right to try legislation, allowing patients to try experimental drugs after approval from a review board and panel of experts. In recent years, the FDA has approved 5,816 of 5,849 requests â€" a 99.4 percent approval rate.

While right to try would eliminate the FDA's role in this process, the legislation does little more than slightly simplify a process that already exists to ensure that those who need experimental medications have access to them.

More harm than good?

Ultimately, we believe right to try is poised to give the Trump administration a political win on a popular public policy but will do little to change the status quo for terminally ill patients. Some opponents say, if anything, it could give terminally ill patients false hope for new access to drugs they already can obtain through existing FDA policy.

Even if right to try does simplify federal regulation, patients must still convince a reticent pharmaceutical industry to provide drugs outside of trials, and patients must still bear the costs for these experimental treatments, which is out of reach for almost all Americans.

The right to try legislation will score the president and members on both sides of the aisle in Congress points, but ultimately it will change little for terminally ill patients and their families.

This article was originally published on The Conversation. This is an updated version of a story first published February 8, 2018.

The Conversation

Featured in Health

  • Pet care costs can top human medical bills

    Pet health care bills can climb into the tens of thousands of dollars as new technologies and treatments drive up costs

  • 7 bad habits that could be wrecking your diet

    If you're having a hard time shedding pounds, try adjusting these common eating habits




Latest From "60 Minutes"

  • Soldiers dispute "friendly fire" report

  • Raising rhino like cattle

  • How did Google get so big?

  • The Theranos deception

  • Mario Batali and The Spotted Pig

  • A rare look at Pope Francis

  • The medical device that has 100,000 women suing

  • Saving a generation

  • Is shock therapy making a comeback?

  •  Play Video

    "Roseanne" canceled after racist tweet

  •  Play Video

    NC community urged to evacuate amid flooding

  •  Play Video

    Puerto Rico hurricane death toll in thousands

  •  Play Video

    Hawaii volcano changing the landscape

  •  Play Video

    Missouri governor resigns amid scandals

Previous Next

Popular On CBS News

  • Ivanka Trump exits media call after questions on Chinese trademarks

  • ABC cancels "Roseanne" after Barr's racist tweet

  • Roseanne Barr apologizes for racist tweet, says she's leaving Twitter

  • Stars react to "Roseanne" cancellation

  • Evacuations canceled after landslide put N.C. dam in danger of failing

  •  24 Photos

    The films that made Harvey Weinstein famous

  •  78 Photos

    Volcanic eruption in Hawaii

  •  26 Photos

    Memorial Day 2018: America honors the fallen

  •  101 Photos

    Prince Harry and Meghan Markle's royal wedding

  •  65 Photos

    Notable deaths in 2018

Previous Next

Latest From CBS News

  • "I'm still alive": Journalist reveals police faked his death to foil plot

  • Cops: Mom made up "kidnap" of baby found dead in diaper box

  • Banned from Amazon? It can happen with too many returns

  • De Beers to sell man-made diamonds

  • Woman punched by cop on N.J. beach speaks out

  • What is "right to tr y" and will it help patients?

New Fire TV App

Source: Google News

« Prev Post
Next Post »